PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Investing in pharmaceutical companies with robust product pipelines and diversified revenue streams is often considered a ...

A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic ...

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

After Pfizer agreed to acquire weight-loss drug developer Metsera for $7.3 billion, Novo Nordisk swooped in with an ...